 Home > Medical News > Medical World News > IAP inhibitor Debio 1143 combined chemotherapy first-line treatment of head and neck cancer significantly extended survival.

IAP inhibitor Debio 1143 combined chemotherapy first-line treatment of head and neck cancer significantly extended survival.

 Last Update: 2020-09-09
 Source: Internet
 Author: User

Tags

advanced process control

high ferritin treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Debiopharm is a Swiss biopharmaceutical company dedicated to the development of innovative therapies for oncology.
recently, the company published convincing three-year follow-up results from the Debio 1143 Random Phase II study on the treatment of high-risk localized advanced head and neck squamous cell carcinoma (LA-SCCHN).
the study evaluated the efficacy and safety of Debio 1143 combined chemotherapy (CRT) and single-use CRT in patients with high-risk LA-SCCHN.
data showed that debio 1143-CRT treatment group had significant statistically and clinically significant improvements in total survival (OS) and a reduced risk of death by half compared to the CRT control group (p-0.0261).
this article is from Bio Valley, for more information please download Bio Valley APP (

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.